Figure 6: Wnt5a increases urine osmolality and apical AQP2 expression in an NDI mouse model.
From: Wnt5a induces renal AQP2 expression by activating calcineurin signalling pathway
(a) Increase in urine osmolality by Wnt5a in the tolvaptan-infused mice. (Left) The C57BL/6 mice were subcutaneously infused with tolvaptan (1.5 mg h−1 kg−1) or DMSO control for 2 days by osmotic minipumps. Tolvaptan-infused mice were intraperitoneally injected with Wnt5a (500 μg kg−1) or PBS, and DMSO-infused control mice were intraperitoneally injected with PBS. After the injection of Wnt5a or PBS, urine was collected within 2 h. (Right) The results are presented in the bar graphs as fold change compared with the value in the control. Tukey, *P<0.05, **P<0.01. (b) Immunofluorescence staining of AQP2 in tolvaptan-infused mouse kidneys. (Upper) The C57BL/6 mice were subcutaneously infused with tolvaptan or DMSO control as in a. Tolvaptan-infused mice were intraperitoneally injected with Wnt5a (500 μg kg−1) or PBS, and DMSO-infused control mice were intraperitoneally injected with PBS for 1 h. Representative collecting duct cells are enlarged in the inset at top left. Scale bars, 10 μm. (Lower) The relative intensities of AQP2 staining from outer to apical membrane (along the arrow) are shown. (c) Western blot analysis of the membrane fraction of AQP2 in mouse kidneys. The C57BL/6 mice were subcutaneously infused with tolvaptan or DMSO control as in a, and then intraperitoneally injected with Wnt5a or PBS as in b.
